HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy.

Abstract
We conducted a population-based study to assess how positron emission tomography (PET) is currently used in patients with Hodgkin lymphoma (HL). Four cancer registries from northern Italy were used to identify patients with HL diagnosed from 2006 to 2008. Computed tomography (CT) and PET scans were collected before treatment start (B), at the end (F), and during treatment (I). One hundred and thirty-six patients were identified as the study population. B-PET, I-PET, and F-PET were performed in 82%, 65%, and 85% of patients, respectively. Overall, I-PET was coded as positive in 16% of cases. F-PET was positive in 13% of cases. The I-PET result was a prognostic factor for failure-free survival (FFS) (hazard ratio [HR] 5.33); the F-PET result was the only prognostic factor for overall survival (OS) (HR 14.2). This population-based study confirms the prognostic role of I-PET for FFS also in daily practice; the results of F-PET can be used to predict OS.
AuthorsStefano Luminari, Marina Cesaretti, Chiara Tomasello, Annalisa Guida, Bruno Bagni, Francesco Merli, Raffaella Postiglione, Lucia Mangone, Annibale Versari, Francesca Re, Vincenzo De Lisi, Livia Ruffini, Stefano Ferretti, Antonio Cuneo, Massimo Federico
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 52 Issue 9 Pg. 1689-96 (Sep 2011) ISSN: 1029-2403 [Electronic] United States
PMID21663500 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
Topics
  • Adolescent
  • Adult
  • Aged
  • Female
  • Fluorodeoxyglucose F18
  • Hodgkin Disease (diagnostic imaging, mortality, pathology, therapy)
  • Humans
  • Italy
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Positron-Emission Tomography
  • Prognosis
  • Radiopharmaceuticals
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: